Apprentice.io, a Jersey City-based company specializing in providing a platform for life science manufacturers to streamline the process of turning molecules into medicine, has successfully raised $65 million in funding. This latest round brings the company’s total funding to an impressive $207 million.
The funding round was led by ICONIQ Growth, with additional support from existing investors, Alkeon Capital Management and Insight Partners. Apprentice plans to utilize the new funds to expand its sales, marketing, and customer success departments.
Under the leadership of CEO Angelo Stracquatanio, Apprentice offers an innovative technology platform that enables life science manufacturers to bring therapeutics to patients in a more efficient manner. The company’s Tempo Manufacturing Cloud plays a crucial role in accelerating the end-to-end drug product lifecycle. It achieves this by connecting distributed teams and sites, facilitating shop floor execution, and providing real-time enterprise-wide visibility.
Currently, 15 of the top 20 US pharmaceutical companies rely on Apprentice.io to expedite the high-quality production of various drugs, targeting a wide range of diseases from COVID to cancer. As the company expands and continues to revolutionize the life science manufacturing industry, it’s clear that the future of drug development and production will be greatly impacted by their innovative solutions.
